{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T08:18:23Z","timestamp":1780733903967,"version":"3.54.1"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.cyto.2025.156862","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T12:45:09Z","timestamp":1737463509000},"page":"156862","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease"],"prefix":"10.1016","volume":"187","author":[{"given":"Katarzyna","family":"Ciepli\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Niedziela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata Kopacz","family":"Rdzanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"S\u0142uszniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Chrapek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwona","family":"Pa\u0142yga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldona","family":"Kowalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.156862_bb0005","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves\u2019 Orbitopathy (Eugogo) Clinical Practice Guidelines for the Medical Management of Graves Orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101620","article-title":"Pathophysiology of thyroid-associated orbitopathy","volume":"37","author":"Lee","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2025.156862_bb0015","series-title":"(eds): Graves\u2019 Orbitopathy: A Multidisciplinary Approach \u2013 Questions and Answers. Basel, Karger","first-page":"41","author":"Salvi","year":"2017"},{"issue":"1","key":"10.1016\/j.cyto.2025.156862_bb0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3390\/jcm13010072","article-title":"Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets","volume":"13","author":"Ciepli\u0144ska","year":"2023","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.cyto.2025.156862_bb0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.beem.2011.10.003","article-title":"Immunopathogenesis of Graves\u2019 ophthalmopathy: the role of the TSH receptor","volume":"26","author":"Iyer","year":"2012","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.cyto.2025.156862_bb0030","author":"Yuanping","year":"2022"},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40618-019-01116-4","article-title":"Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy","volume":"43","author":"Hai","year":"2020","journal-title":"J. Endocrinol. Investig."},{"issue":"14","key":"10.1016\/j.cyto.2025.156862_bb0040","article-title":"A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves\u2019 orbitopathy","volume":"19","author":"Cui","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.cyto.2025.156862_bb0050","series-title":"Graves\u2019 Orbitopathy: A Multidisciplinary Approach \u2013 Questions and Answers. Basel, Karger","first-page":"41","author":"Salvi","year":"2017"},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41433-018-0279-9","article-title":"The  involvement  of  T  cell pathogenesis  in  thyroid-associated  ophthalmopathy","volume":"33","author":"Huang","year":"2019","journal-title":"Eye\u00a0 \u00a0(Lond)."},{"issue":"13","key":"10.1016\/j.cyto.2025.156862_bb0060","article-title":"Research progress on the pathogenesis of Graves\u2019 ophthalmopathy: Based on immunity, noncoding RNA and exosomes","volume":"23","author":"Zheng","year":"2022","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2025.156862_bb0065","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1210\/jc.2005-2813","article-title":"Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease","volume":"91","author":"Eckstein","year":"2006","journal-title":"The Journal of Clinical Endocrinology & Metabolism."},{"key":"10.1016\/j.cyto.2025.156862_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.648732","article-title":"Mechanisms That Underly T Cell Immunity in Graves\u2019 Orbitopathy","volume":"12","author":"Fang","year":"2021","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"10.1016\/j.cyto.2025.156862_bb0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.7.28","article-title":"The Potential of Artemisinins as Novel Treatment for Thyroid Eye Disease by Inhibiting Adipogenesis in Orbital Fibroblasts","volume":"64","author":"Guo","year":"2023","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.cyto.2025.156862_bb0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.exer.2015.02.007","article-title":"Current perspectives on the role of orbital fibroblasts  in  the  pathogenesis  of  Graves\u2019  ophthalmopathy","volume":"142","author":"Dik","year":"2016","journal-title":"Exp. Eye Res."},{"issue":"3","key":"10.1016\/j.cyto.2025.156862_bb0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.beem.2011.10.003","article-title":"Immunopathogenesis of Graves\u2019 ophthalmopathy: the role of the TSH receptor","volume":"26","author":"Iyer","year":"2012","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"21","key":"10.1016\/j.cyto.2025.156862_bb0090","doi-asserted-by":"crossref","first-page":"15794","DOI":"10.1074\/jbc.M109.074534","article-title":"Mast cell-derived prostaglandin D2 controls hyaluronan synthesis in human orbital fibroblasts via DP1  activation:  implications  for  thyroid  eye  disease","volume":"285","author":"Guo","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cyto.2025.156862_bb0095","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/jcem.87.1.8164","article-title":"Orbital  fibroblast  heterogeneity  may  determine  the  clinical  presentation  of thyroid-associated ophthalmopathy","volume":"87","author":"Smith","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.cyto.2025.156862_bb0100","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMra052723","article-title":"The  many  roles  of  chemokines  and  chemokine receptors in inflammation","volume":"354","author":"Charo","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0105","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/1521-4141(200202)32:2<477::AID-IMMU477>3.0.CO;2-U","article-title":"Fibroblast subsets in the human orbit: Thy-1+ and  Thy-1-  subpopulations  exhibit  distinct  phenotypes","volume":"32","author":"Koumas","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2025.156862_bb0110","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1089\/thy.2007.0407","article-title":"Immune mechanisms in thyroid eye disease","volume":"18","author":"Lehmann","year":"2008","journal-title":"Thyroid"},{"issue":"14","key":"10.1016\/j.cyto.2025.156862_bb0115","doi-asserted-by":"crossref","first-page":"1163633","DOI":"10.3389\/fimmu.2023.1163633","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"16","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2025.156862_bb0120","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.immuni.2016.04.017","article-title":"Co-stimulatory and Co-inhibitory Pathways in Autoimmunity","volume":"44","author":"Zhang","year":"2016","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.cyto.2025.156862_bb0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s12276-018-0130-1","article-title":"Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance","volume":"50","author":"Park","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.cyto.2025.156862_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(17)30607-1","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156862_bb0135","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2013.183","article-title":"Targeting co-stimulatory pathways: transplantation and autoimmunity","volume":"10","author":"Ford","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.cyto.2025.156862_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645699","article-title":"Immune Checkpoints, a Novel Class of Therapeutic Targets for Autoimmune Diseases","volume":"12","author":"Zhai","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156862_bb0145","doi-asserted-by":"crossref","unstructured":"Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1\/PD-Ls pathway and autoimmune diseases. Cell. Immunol. 2014;290(1):72-9. doi: https:\/\/doi.org\/10.1016\/j.cellimm.2014.05.006. Epub 2014 May 27. PMID: 24908630.","DOI":"10.1016\/j.cellimm.2014.05.006"},{"issue":"21","key":"10.1016\/j.cyto.2025.156862_bb0150","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1002\/cam4.3410","article-title":"Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med."},{"issue":"14","key":"10.1016\/j.cyto.2025.156862_bb0155","article-title":"The role of PD-1 signaling in health and immune-related diseases","volume":"16","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2025.156862_bb0160","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat. Immunol."},{"issue":"13","key":"10.1016\/j.cyto.2025.156862_bb0165","article-title":"Biological Characteristics and Clinical Significance of Soluble PD-1\/PD-L1 and Exosomal PD-L1 in Cancer","volume":"21","author":"Niu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156862_bb0170","series-title":"Role of sPD-1 and sPD-Ls in the pathogenesis of connective tissue disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Mar 28;48(3):444-454. English, Chinese. doi: 10.11817\/j.issn.1672-7347.2023.220263. PMID: 37164928","author":"He","year":"2023"},{"issue":"11","key":"10.1016\/j.cyto.2025.156862_bb0175","article-title":"The significance of PD-1\/PD-L1 imbalance in ulcerative colitis","volume":"31","author":"Shi","year":"2023","journal-title":"PeerJ"},{"issue":"1","key":"10.1016\/j.cyto.2025.156862_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/sji.12884","article-title":"Serum levels of soluble programmed death-1 (sPD-1) and soluble programmed death ligand 1(sPD-L1) in systemic lupus erythematosus: Association with activity and severity","volume":"92","author":"Du","year":"2020","journal-title":"Scand. J. Immunol."},{"issue":"14","key":"10.1016\/j.cyto.2025.156862_bb0185","article-title":"The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study","volume":"11","author":"Kurosaki","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0190","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/1756-185X.13391","article-title":"Influence of total glucosides of paeony on PD-1\/PD-L1 expression in primary Sj\u00f6gren\u2019s syndrome[J]","volume":"22","author":"Chen","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.cyto.2025.156862_bb0195","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3389\/fimmu.2018.01677","article-title":"Smoking is associated with low levels of soluble PD-L1 in rheumatoid arthritis[J]","volume":"9","author":"Was\u00e9n","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cyto.2025.156862_bb0200","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/0961203320916517","article-title":"Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity[J]","volume":"29","author":"Hirahara","year":"2020","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.cyto.2025.156862_bb0205","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis[J]","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheum."},{"issue":"8","key":"10.1016\/j.cyto.2025.156862_bb0210","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/1346-8138.13339","article-title":"Serum levels of soluble programmed death-1 and programmed death ligand-1 in systemic sclerosis: association with extent of skin sclerosis[J]","volume":"43","author":"Yanaba","year":"2016","journal-title":"J. Dermatol."},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0215","first-page":"116","article-title":"Serum soluble programmed cell death protein 1 could predict the current activity and severity of antineutrophil cytoplasmic antibody-associated vasculitis: a monocentric prospective study[J]","volume":"37","author":"Yoon","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.cyto.2025.156862_bb0220","doi-asserted-by":"crossref","unstructured":"Greisen SR, Rasmussen TK, Stengaard-Pedersen K, Hetland ML, H\u00f8rslev-Petersen K, Hvid M, Deleuran B. Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis. Scand. J. Rheumatol. 2014;43(2):101-8. doi: https:\/\/doi.org\/10.3109\/03009742.2013.823517. Epub 2013 Nov 1. PMID: 24182347.","DOI":"10.3109\/03009742.2013.823517"},{"key":"10.1016\/j.cyto.2025.156862_bb0225","series-title":"The expression and clinical significance of soluble form of costimulatory molecule PD-1 in rheumatoid arthritis[D]","author":"Li","year":"2012"},{"key":"10.1016\/j.cyto.2025.156862_bb0230","series-title":"Concentration determination and significance of serum soluble Co-signalling molecules sPD-1 and sPD-L1 in patients with rheumatoid arthritis[D]","author":"Qi","year":"2011"},{"issue":"7","key":"10.1016\/j.cyto.2025.156862_bb0235","first-page":"805","article-title":"Diagnostic value of serum sPD-1 and sPD-L1 for rheumatoid arthritis and their correlation with disease activity[J]","volume":"46","author":"Longyan","year":"2021","journal-title":"J. Guizhou Med. Univ."},{"key":"10.1016\/j.cyto.2025.156862_bb0240","doi-asserted-by":"crossref","DOI":"10.1007\/s00125-023-06075-3","article-title":"Progression of type 1 diabetes is associated with high levels of soluble PD-1 in islet autoantibody-positive children","author":"Bruzzaniti","year":"2024","journal-title":"Diabetologia"},{"issue":"8","key":"10.1016\/j.cyto.2025.156862_bb0245","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves\u2019 ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.cyto.2025.156862_bb0250","article-title":"PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.156862_bb0255","series-title":"Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves\u2019 ophthalmopathy in comparison to hyperthyroid patients without","author":"Khamisi","year":"2025"},{"issue":"5","key":"10.1016\/j.cyto.2025.156862_bb0260","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1210\/jc.2009-2470","article-title":"A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves\u2019 orbitopathy","volume":"95","author":"Lytton","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.cyto.2025.156862_bb0265","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaophthalmol.2018.0806","article-title":"Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopath y","volume":"136","author":"Rotondo Dottore","year":"2018","journal-title":"JAMA Ophthalmol."},{"issue":"1","key":"10.1016\/j.cyto.2025.156862_bb0270","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/IOP.0000000000001161","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"issue":"6","key":"10.1016\/j.cyto.2025.156862_bb0275","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0280","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur. J. Endocrinol."},{"issue":"14","key":"10.1016\/j.cyto.2025.156862_bb0285","article-title":"Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells","volume":"17","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2025.156862_bb0290","first-page":"397","article-title":"Immunomodulatory effects of costimulatory molecules sPD-1 and OX40 on splenic CD4+ T cells and serum cytokines in arthritic mice[J]","volume":"37","author":"Yanyan","year":"2021","journal-title":"Immunol. J."},{"issue":"2","key":"10.1016\/j.cyto.2025.156862_bb0295","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/eje.0.1430197","article-title":"Serum concentrations of proinflammatory cytokines in Graves\u2019 disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking","volume":"143","author":"Salvi","year":"2000","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.cyto.2025.156862_bb0300","first-page":"160","article-title":"Serum pro- and anti-inflammatory cytokines in patients with Graves\u2019 disease with ophthalmopathy during treatment with glucocorticoids","volume":"44","author":"My\u015bliwiec","year":"1999","journal-title":"Rocz Akad Med Bialymst."},{"issue":"3","key":"10.1016\/j.cyto.2025.156862_bb0305","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/02713680601186698","article-title":"The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy","volume":"32","author":"Lacka","year":"2007","journal-title":"Curr. Eye Res."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T07:41:06Z","timestamp":1738741266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":61,"alternative-id":["S1043466625000092"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156862","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.156862","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156862"}}